The smallest change
A methyl group is one carbon atom and three hydrogens. It is about as small a chemical addition as you can make. Chapter 10 of Peptide Synthesis and Applications, by Renée Roodbeen and Knud Jensen at the University of Copenhagen, shows how adding a single methyl group in the right place on a peptide can change what it does dramatically.
Where the methyl goes
Every amino acid in a peptide chain (except proline) has a nitrogen in the backbone with a hydrogen attached: the N-H of the peptide bond. That hydrogen matters. It forms hydrogen bonds that help the chain fold into helices and sheets, and it helps enzymes recognise and cut the chain.
N-methylation replaces that hydrogen with a methyl group. The introductory chapter explains the effects: it removes a hydrogen bond donor, and it changes the balance between two possible geometries of the peptide bond (cis and trans), which affects the shape of the surrounding sequence.
Nature did it first
The chapter notes that bioactive N-methylated peptides are often found in natural sources, such as marine sponges. The best known example outside the book is cyclosporine, the immunosuppressant drug that transformed organ transplantation. It is a small cyclic peptide with seven N-methylated amino acids, and it is famous among peptide chemists for something unusual: it can be taken by mouth.
That is not a coincidence. The chapter states that N-methylation may improve a peptide's pharmacokinetic properties by improving oral availability and extending its half-life in the body.
Why it helps: three effects
1. Enzymes find it harder to cut. Proteases recognise the normal peptide backbone. A methylated nitrogen changes the local structure and blocks some of that recognition.
2. It can cross membranes more easily. Those N-H groups love water. Replacing some with methyl groups makes the peptide slightly less water-loving, which can help it slip through the fatty membranes of gut cells.
3. It locks the shape. By changing which geometries the backbone can adopt, a methyl group can hold a peptide in its active shape, making it bind its target more tightly and more selectively.
The Cilengitide example
The chapter's headline example shows the third effect clearly.
Cilengitide is a small cyclic peptide discovered by Horst Kessler's group and developed by Merck-Serono. It targets a family of cell surface receptors called integrins, which help cells attach to their surroundings and are involved in tumour blood vessel growth. It was evaluated as a treatment for glioblastoma, an aggressive brain cancer.
The original, non-methylated cyclic peptide bound its target integrin (αvβ3) with an IC50 of 2.5 nanomolar. IC50 is the concentration needed for half the maximum effect, so lower means more potent.
Adding a single methyl group to one valine lowered that to 0.58 nanomolar. Roughly four times more potent from one carbon atom.
Selectivity improved too. The chapter's figure shows the methylated version discriminating between the target integrin and a related one on blood platelets roughly twice as well (a selectivity ratio of about 1,483 versus 680).
The chapter also mentions N-methylation being used to design somatostatin analogues with altered receptor selectivity and reduced neurogenic inflammation.
(For completeness: Cilengitide ultimately did not succeed in its main phase 3 trial for glioblastoma. The chemistry worked; the medicine did not. That happens often in drug development, and it is a useful reminder that improving how a molecule binds is not the same as improving outcomes in patients.)
The N-methyl scan
One of the most practical ideas in the chapter is the N-methyl scan. Since you cannot predict in advance which methylation will help, chemists make a series of versions of a peptide, each with a methyl group on a different backbone nitrogen, and test them all.
The chapter's on-resin method makes this fast: instead of buying expensive pre-methylated building blocks for each position, chemists methylate the growing chain directly while it is still attached to the resin, using a three-step process of protecting, methylating and deprotecting the nitrogen.
The difficulty: coupling onto a methyl
There is a catch. Once a nitrogen carries a methyl group, it becomes crowded and much harder to attach the next amino acid to it. The chapter notes that coupling onto an N-methylated residue can require harsh or expensive reagents and long reaction times.
How hard depends on the neighbours. Coupling onto N-methyl glycine is straightforward. Coupling onto N-methyl isoleucine at room temperature is very difficult. The chapter shows that microwave heating greatly improves these difficult couplings.
It also includes a safety note worth mentioning: the direct methylation reagents are generally carcinogenic, and methylating near cysteine and histidine risks methylating their side chains too.
Why this matters to you
N-methylation explains something that puzzles many people: why most peptide drugs are injected, while a few can be swallowed. Oral peptides are hard because peptides are fragile and water-loving. N-methylation, ring structures (Part 3) and other modifications are among the tools chemists use to overcome both problems.
It also shows how much of peptide drug design happens at the level of single atoms. The difference between a moderate molecule and a potent, selective one can be one carbon atom placed on one nitrogen. That is why two peptides with nearly the same sequence can behave completely differently, and why "it's basically the same peptide" is rarely true.
This series explains laboratory chemistry for general readers. It is not a guide to making or using any compound. Nothing here is medical advice.
